Altamira Entered into an Exclusive License and Distribution Agreement with Nuance Pharma to Develop and Commercialize Bentrio Nasal Spray
Shots:
- Altamira to receive $1M up front & is eligible to receive ~$3M as development milestones & ~$19.5M as commercial milestones, following initial supply of Bentrio to Nuance along with royalties, following the start of local production of Bentrio by Nuance
- Nuance gets the right to develop & commercialize Bentrio nasal spray in Chinese Mainland, Hong Kong, Macau & South Korea & will be responsible for the local production of the product
- Bentrio (AM-301) is a drug-free nasal spray used for personal protection against airborne viruses & allergens. The therapy was effective in slowing the growth of the viral titer, following the treatment of 24 or 30 hrs. after infection
Ref: Altamira | Image: Altamira
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
